Healthcare
Leaders advancing medicine, biotechnology, care delivery and health institutions.
Demis Hassabis Moved DeepMind Deeper Into the Laboratory. Scientific AI Needs a Verification Business Model
Demis Hassabis is building a wider scientific-AI stack around AlphaGenome and Co-Scientist. The opportunity is large, but laboratories need reproducible gains rather than fluent novelty.
Chuan He Connected Diet, RNA Marks and Early Immunity. Product Builders Must Separate Signal From Platform
Chuan He’s latest research brings RNA regulation into early-life immunity, learning and development. The opportunity is broad, but commercial claims must stay behind causal evidence.
Reshma Kewalramani Has Opened Vertex's Fourth Franchise. Kidney Medicine Must Now Match the Cystic Fibrosis Standard
Vertex is building beyond cystic fibrosis, with kidney medicine its newest large opportunity. Reshma Kewalramani must turn povetacicept into a durable franchise.
Shimon Sakaguchi Extended Treg Science Into Cancer and Heart Failure. Translation Must Now Prove Its Range
Shimon Sakaguchi’s 2026 research links Treg biology to checkpoint response and heart-failure fibrosis. Platform value will depend on reproducibility, manufacturing and patient selection.
Yoshinori Ohsumi Put Nobel Capital Into Basic Research. Autophagy’s Drug Pipeline Still Has to Deliver
Yoshinori Ohsumi's fund is backing young researchers whose work may need years to mature. The latest autophagy drug programmes show why Asia needs capital structures that can absorb scientific uncertainty without confusing a celebrated mechanism with a de-risked market.
Vasant Narasimhan Remade Novartis as a Pure-Play Medicines Company. New Launches Must Outrun the Patent Cycle
Novartis is strategically simpler but commercially exposed to patent erosion. Vasant Narasimhan's next test is making new medicines grow faster than older franchises decline.
Jay Bhattacharya Is Rewriting How America Funds Medical Science. The Portfolio Test Starts Now
Jay Bhattacharya has secured room to reshape the world’s most influential biomedical funder. His challenge is to make risk-taking, replication and real-world data produce better science without turning grant selection into an opaque policy instrument.
Ryusuke Hamaguchi Took His Japanese Method Into a Four-Country Production. Now Theatrical Economics Must Catch Up
‘Soudain’ proved Ryusuke Hamaguchi can scale his method through a European-Japanese co-production. Its long theatrical journey will test the business around auteur cinema.
